系统性红斑狼疮患者骨髓基质细胞生长特性与相关细胞因子的表达

背景：骨髓造血依赖于干细胞所处的造血微环境，其中基质细胞及多种细胞因子在造血中发挥着重要的调控作用。系统性红斑狼疮具有淋巴细胞亚群及相关细胞因子表达，其基质细胞及细胞因子的异常可能导致造血微环境异常，损伤造血功能。 目的：观察体外培养系统性红斑狼疮基质细胞的生长特性及细胞因子白细胞介素6、白细胞介素8的表达，探讨细胞因子与系统性红斑狼疮活动的关系，阐明系统性红斑狼疮慢性病贫血可能的病理机制。 设计、时间及地点：细胞学体外培养，病例-对照观察，于2008-01/12在大连医科大学附属第二医院血液风湿科及血液学实验室完成。 对象：选择大连医科大学附属第二医院血液风湿科收治的活动期系统性红斑狼疮患者15例(实验组)，男1例，女14例，中位年龄32(20~55)岁；合并慢性病贫血者7例，无贫血者8例。另选健康个体10名作为对照，男9名，女1名，中位年龄46(38~57)岁。 方法：取系统性红斑狼疮患者及健康对照者的骨髓液分离单个核细胞培养。 主要观察指标：系统性红斑狼疮患者及健康对照者骨髓基质细胞生长特性及体外培养上清白细胞介素6和白细胞介素8的水平。 结果：系统性红斑狼疮患者骨髓基质细胞较健康对照生长及集落形成均延后，合并慢性病贫血的系统性红斑狼疮患者更加明显，集落内各细胞排列欠规整有序。与健康对照者相比，系统性红斑狼疮患者骨髓基质细胞体外培养上清细胞因子白细胞介素6、白细胞介素8的表达显著升高(P < 0.01)，并且与系统性红斑狼疮的疾病活动呈正相关。 结论：由于系统性红斑狼疮基质细胞可能存在功能的缺陷，并且高表达细胞因子如白细胞介素6、白细胞介素8，损伤了骨髓微环境，最终导致系统性红斑狼疮患者造血功能异常。细胞因子可能成为系统性红斑狼疮疾病活动的标志。     

Micro-RNAs在肝纤维化发生中的作用

1993年Lee et al在秀丽新小杆线虫中发现编码形成可抑制LIN-14蛋白合成,大小为22 nt的小分子RNA基因lin-4,当时并未引起注意.直到2000年,Reinhart et al又在此线虫中发现第二种类似的基因let-7,此后不到一年间又相继发现了数百种类似的小分子RNA,被称为micro-RNAs(miRNAs).近年来,miRNAs的研究突飞猛进.miRNAs与肿瘤发生发展的关系及其潜在的诊断价值是目前研究的热点之一,且在非肿瘤疾病中,miRNAs的研究方兴未艾.现将与肝纤维化发生有关的miRNAs研究作一简介.     

百应胶囊治疗银屑病的实验性药效学研究

<正>本研究根据银屑病的病理特点,采用小鼠阴道上皮细胞有丝分裂模型[1],探讨百应胶囊对银屑病的治疗效果。     

Changes in T .lymphocyte subsets after severe traumatic brain inJury

BACKGROUND： Besides local changes of cranial parenchymal cells, hemorrhage, etc., severe traumatic brain injuries also cause the changes of total body fluid and various functions, and the changes of lymphocytes and T lymphocyte subsets should be paid more attention to. OBJECTIVE： To reveal the changing laws of T lymphocyte subsets after severe traumatic brain injury, and compare with mild to moderate brain injury. DESIGN： A comparative observation. SETTINGS： Department of Neurosurgery, Longgang District Buji People＇s Hospital of Shenzhen City; Central Laboratory of Shenzhen Hospital of Prevention and Cure for Chronic Disease. PARTICIPANTS： All the subjects were selected from the Department of Neurosurgery, Longgang District Buji People＇s Hospital of Shenzhen City from August 2002 to August 2005. Thirty patients with severe brain injury, whose Glasgow coma score （GCS） was ≤ 8 points, were taken as the experimental group, including 21 males and 9 females, aging 16 - 62 years. Meanwhile, 30 patients with mild traumatic brain injury were taken as the control group （GCS ranged 14- 15 points）, including 18 males and 12 females, aging 15 -58 years. All the subjects were in admission at 6 hours after injury, without disease of major organs before injury Informed consents were obtained from all the patients or their relatives. METHODS： （1） The T lymphocytes and the subsets in peripheral blood were detected with immunofluorescent tricolor flow cytometry at l, 3, 7 and 14 days after injury in both groups. （2） The conditions of pulmonary infections were observed at 4 days after injury. The differences of measurement data were compared with the t test. MAIN OUTCOME MEASURES： Changes of T lymphocytes subsets at 1 - 14 days after severe and mild or moderate traumatic injury. RESULTS： Finally, 28 and 25 patients with mild to moderate traumatic brain injury, whereas 25 and 21 patients with severe traumatic brain injury were analyzed at 7 and 14 days respectively, and the missed ones died due to the development of disease. （1） Changes of T lymphocyte subsets： At 1 and 3 days after injury, CD3, CD4, CD8, CD4/CD8 began to decrease, whereas CD8 increased in the experimental group, which were very significantly different from those in the control group （t =2.77 - 3.26, P 〈 0.01）, and began to recover at 7 days, which were significantly different from those in the control group （t = 2.06 - 2.24, P 〈 0.05）, and generally recovered to the normal levels at 14 days （P 〉 0.05）. （2） Conditions of pulmonary infections： At 4 days after injury, the rate of pulmonary infection was significantly different between the experimental group and control group [73% （22/30）, 0, x2=37.29, P 〈 0.01]. CONCLUSION： Patients with severe traumatic brain injury suffer from damages of cellular immune function at early period （within 7 days）, and they are easily to be accompanied by pulmonary infections.     

血细胞分离术在治疗高细胞白血病中的应用

高细胞性白血病(HLAL)通常指W BC>100×109/L的白血病,约占急性白血病的5%~20%[1],常伴有高粘滞综合征的症状,易发生颅内出血,死亡率高,缓解率低。目前对此类疾病的治疗以化疗为主,但是化疗时常因化疗药物剂量较大而损伤正常造血干细胞及其他重要器官,同时化疗后易出现D IC、肿瘤溶解综合征等,甚至危及患者生命。我们用血细胞分离机对22例患者在化疗前分离去除白血病细胞,然后再用联合化疗治疗,取得较满意效果,现报告如下。1资料与方法1.1病例资料22例病例均为本院2001年1月至2004年12月住院患者,按FAB标准其中急性白血病13例,男8例,…     

患丙型肝炎的肝移植病人的免疫抑制及转归（下）

在特异性免疫抑制剂对丙型肝炎移植病人长期结果的影响方面，存在一些疑惑，使用皮质醇治疗急性细胞排斥对感染HCV的接受是有害的。多年前，Kings学院医院Ed Gane和同事表示皮质醇片剂与血清中HCVRNA浓度增加4到100倍有关。较高的HCV RNA水平也与复发性肝炎的组织学严重程度增加有关。他们也表示皮质醇片剂与急性肝炎和较早时间复发的频率增加有关。     

常见细菌与病毒利用自然机制侵入细胞

据医学空间网2月10日报道，科学家最新的研究成果显示，细菌和病毒是利用一种自然机制侵入人体细胞内部并生长。 美国乔治亚医学院肿瘤病理学专家耶哈一达卡表示，这些病原体在得到活性以后，它们进入细胞内部的方式与细胞表面数百万接受器例行进入细胞的方式相同。     

胰腺癌黏蛋白4基因修饰的树突状细胞疫苗构建及对胰腺癌细胞的免疫效应

Objective To obtain the dendritic cells ( DC)-based vaccine modified by adenovirus containing MUC4 gene , and evaluate the anti-tumor efficacy of DC vaccine to pancreatic tumor cells. Meth-ods The mRNA sequence of tumor associated antigen, MUC4, was obtained from NCBI, and MUC4 se-quence was acquired through the restriction enzyme sites and over lap PCR, then subcloned into adenovirus plasmid to create recombinant adenovirus ( rAd-MUC4) . The DCs were infected by rAd-MUC4 virus and then stimulated the lymph cells from the same donor to induce MUC4 specific cytotoxicity T lympbocytes ( CTL) . The efficacy of CTL was analyzed by LDH releasing assay. Elispot was used to detect the IFN-γ release. Results The recombinant adenovirus containing MUC4 ( sv12) gene was obtained. The MUC4-induced CTL could specifically kill the Capan-1 pancreatic tumor cells [ ( 13. 7±6.0)% , ( 21.4± 4. 7)% , (36.1±9. 5)% at ratios of 10: ,20: ,40: ] , higher than MCF-7 and Bxpc-3 cells respectively, P < 0. 05. The spots number of CTL induced by rAd-MUC4 was ( 139.1±23.3) , more than GFP and PBS control group,P<0.05. Conclusion The Muc4 gene modified DC vaccine could induce the proliferation of CTL, which provided a significant cytotoxicity to HLA-matched MUC4 positive tumor cell lines in vitro.     

紫杉醇抗癌研究荟萃

多烯紫杉醇卡铂与紫杉醇卡铂可用于卵巢癌一线化疗一般认为,含铂类和紫杉烷的药物是治疗卵巢癌的标准化疗。英国研究人员将多烯紫杉醇卡铂(Ⅰ组)与紫杉醇卡铂(Ⅱ组)用于1077例Ⅰc-Ⅳ期卵巢上皮癌或原发性腹膜癌的一线化疗。中数为23个月的随访显示,两组的无进展生存时间(progression—freesurvival,PFS)相似。Ⅰ组和Ⅱ组2年整体生存率(overallsurvivalrates,OSR)分别是62.4%和68.9%。但Ⅰ组3～4级粒细胞减少及由此引起的并发症呈统计学意义增多,尽管其骨髓抑制并未影响用药剂量或患者生命安全。两组综合生活质量(Globalqualityoflife)相似(JNatlCancerInst,2004,96:1682-1691)。